Compass gains as psychedelic therapy succeeds in late-stage trial for depression

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...

Compass' psychedelic-based depression treatment scores second late-stage study win

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Compass Pathways Phase 3 Results Raise Hopes For FDA Approval Of Psilocybin

Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
BioWorld

Compass nears NDA as psilocybin scores again in depression

Danaher Corp. has agreed to acquire Masimo Corp. for $9.9 billion in a move to strengthen its diagnostics business. Under the terms of the agreement, Danaher will acquire all the outstanding shares of ...
BioPharma Dive

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Rasmussen Reports

Daily Presidential Tracking Poll

The Rasmussen Reports daily Presidential Tracking Poll for Friday shows that 47% of Likely U.S. Voters approve of President Trump’s job performance. Fifty-one (51%) disapprove. The latest figures ...
Global News

CKNW homepage

$10-a-day daycare program paused in order to stabilize, B.C. government says $10-a-day daycare program paused in order to stabilize, B.C. government says The province says the goal is to stabilize the ...